Evidence map›Paper›PMID 27040325›Full record

ArticleJournal of clinical laboratory analysis2016

Development of Unlabeled Probe Based High-Resolution Melting Analysis for Detection of Filaggrin Gene Mutation c.3321delA.

Wei-Long Zhong, Luo Wang, Xia Wu, Jie Zhang, Xiao-Fan Chen, Wei Zhang, Xia Dou, Bo Yu

Abstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Wei-Long ZhongDepartment of Dermatology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, P.R. China.
Luo WangShenzhen Key Laboratory for Translational Medicine of Dermatology, Shenzhen Peking University-the Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, P.R. China.
Xia WuDepartment of Dermatology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, P.R. China.
Jie ZhangDepartment of Dermatology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, P.R. China.
Xiao-Fan ChenShenzhen Key Laboratory for Translational Medicine of Dermatology, Shenzhen Peking University-the Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, P.R. China.
Wei ZhangShenzhen Key Laboratory for Translational Medicine of Dermatology, Shenzhen Peking University-the Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, P.R. China. zhangweispace@yeah.net.
Xia DouDepartment of Dermatology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, P.R. China. douxia@medmail.com.cn.
Bo YuDepartment of Dermatology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, P.R. China. yubomd@hotmail.com.
Peking University Shenzhen Hospital · CNUniversity of Hong Kong · HKHong Kong University of Science and Technology · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFilaggrin gene (FLG) plays an important role in skin barrier function, and loss-of-function mutations of FLG have been shown to be a predisposing factor for atopic dermatitis (AD). The c.3321delA mutation is the most common FLG mutation in Chinese population. We aim to develop a rapid, cost-efficiency, and reliable closed-tube method that has not been described for the detection of c.3321delA mutation.

methodsRecombinant wild-type and mutant plasmids of c.3321delA mutation were constructed, heterozygous mutant plasmids were prepared by mixing the mutant plasmids and wild-type plasmids at 1:1 ratio. High-resolution melting analysis (HRMA) coupled with an unlabeled DNA probe was employed to identify the shift in melting temperature of the probe-template complex, which reflects the presence of c.3321delA mutation.

resultsUnlabeled probe based HRMA was able to distinguish all three genotypes (wild-type, heterozygote, and mutant) of c.3321delA mutation. Then, we applied this method to genotype 1,317 clinical samples. Genotyping results obtained from unlabeled probe HRMA were 100% concordant with the results from direct sequencing.

conclusionWe developed a fast and high-throughput method to detect the c.3321delA mutation.

Indexed as

Alzheimer DiseaseDNA Mutational AnalysisFemaleFilaggrin ProteinsGenotypeHumansIntermediate Filament ProteinsMaleNucleic Acid Amplification TechniquesSequence DeletionFilaggrin ProteinsFLG protein, humanIntermediate Filament Proteinsatopic dermatitisc.3321delA mutationfilaggrin geneskin barrierunlabeled probe based high-resolution melting analysis

Identifiers

PMID27040325
PMCPMC6806714
OpenAlexW2318321777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.